{"organizations": [], "uuid": "b10019c45c284a79f760e1e76648af46b78857c5", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-heat-biologics-reports-data-from-p/brief-heat-biologics-reports-data-from-phase-2-trial-of-hs-410-combined-with-bacillus-calmette-gurin-for-treating-non-muscle-invasive-bladder-cancer-idUSFWN1R80MD", "country": "US", "domain_rank": 408, "title": "BRIEF-Heat Biologics Reports Data From Phase 2 Trial Of HS-410 Combined With Bacillus Calmette-Guérin For Treating Non-Muscle Invasive Bladder Cancer", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-26T14:50:00.000+03:00", "replies_count": 0, "uuid": "b10019c45c284a79f760e1e76648af46b78857c5"}, "author": "", "url": "https://www.reuters.com/article/brief-heat-biologics-reports-data-from-p/brief-heat-biologics-reports-data-from-phase-2-trial-of-hs-410-combined-with-bacillus-calmette-gurin-for-treating-non-muscle-invasive-bladder-cancer-idUSFWN1R80MD", "ord_in_thread": 0, "title": "BRIEF-Heat Biologics Reports Data From Phase 2 Trial Of HS-410 Combined With Bacillus Calmette-Guérin For Treating Non-Muscle Invasive Bladder Cancer", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-heat biologics reports data from", "sentiment": "neutral"}, {"name": "brief-heat biologics reports data from phase", "sentiment": "neutral"}, {"name": "reuters) - heat biologics inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Market News March 26, 2018 / 11:51 AM / Updated 5 minutes ago BRIEF-Heat Biologics Reports Data From Phase 2 Trial Of HS-410 Combined With Bacillus Calmette-Guérin For Treating Non-Muscle Invasive Bladder Cancer Reuters Staff 1 Min Read March 26 (Reuters) - Heat Biologics Inc: * HEAT BIOLOGICS - REPORTS 2 YEAR DATA FROM PHASE 2 TRIAL OF HS-410 COMBINED WITH BACILLUS CALMETTE-GUÉRIN FOR TREATING NON-MUSCLE INVASIVE BLADDER CANCER * HEAT BIOLOGICS - WITHIN SUBGROUP OF PATIENTS WHO RECEIVED LOW DOSE OF CO'S IMPACT HS-410 WITH BCG, 10 OUT OF 10 REMAINED DISEASE FREE AFTER 2-YRS Source text: ( bit.ly/2pGwsuk ) Further company coverage:", "external_links": [], "published": "2018-03-26T14:50:00.000+03:00", "crawled": "2018-03-26T15:03:29.024+03:00", "highlightTitle": ""}